SUMO2/3 Antibody

Immunofluorescence: 1-2ug/ml,Immunohistochemistry (FFPE): 2-4ug/ml for 30 min at RT

Optimal dilution of the antibody should be determined by the researcher.

This mAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Recombinant human protein was used as the immunogen for this SUMO-2/3 antibody.

This SUMO-2/3 antibody is available for research use only.

Predominantly nuclear with some cytoplasmic

Protein G affinity chromatography

P61956